Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Core Insights - Autolus Therapeutics plc is set to present new data on its CAR-T cell therapy AUCATZYL® at the 2025 Tandem Meetings, highlighting its cost-effectiveness and clinical outcomes compared to other therapies [1][2]. Group 1: Presentations and Findings - The company will deliver an oral presentation and three poster presentations at the upcoming conference, focusing on the economic model comparing AUCATZYL® with other CAR-T therapies [1]. - An updated health economic cost model indicates that AUCATZYL® has a shorter duration and lower incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), leading to reduced healthcare costs [2]. - A poster presentation will detail the economic model comparing costs associated with CRS and ICANS among patients treated with CAR-T therapies for relapsed/refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL), showing that AUCATZYL® is associated with lower healthcare costs compared to brexu-cel [4]. Group 2: Clinical Outcomes - An oral presentation will discuss risk factors associated with sub-optimal outcomes and hematotoxicity following treatment with obe-cel for R/R B-ALL, emphasizing the potential for risk stratification to identify patients who may benefit from treatment [3]. - A poster will compare the efficacy and safety outcomes of obe-cel versus non-CAR T-cell standard of care therapies, demonstrating higher overall response rates (ORR) and longer overall survival (OS) and event-free survival (EFS) for obe-cel [5]. - Another poster will present findings that deep molecular remission predicts better clinical outcomes in adults treated with obe-cel, with 84% of responders achieving measurable residual disease (MRD) <10 leukemic cells, correlating with improved EFS and OS rates [6][7]. Group 3: Company Overview - Autolus Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases, with an FDA-approved product, AUCATZYL, and a pipeline of candidates in development [8]. - The company utilizes proprietary T cell programming technologies to create targeted and effective therapies designed to overcome the limitations of existing treatments [8]. - AUCATZYL is specifically indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, showcasing the company's commitment to addressing significant unmet medical needs in oncology [11].